Capricor TherapeuticsCAPR -0.30%37 PB Ratio is 6.11 as of Jun. 24, 2026, which is 49% above its 10-year median of 4.11. GuruFocus rates CAPR with a GF Score™ of 37/100 and a GF Value™ of $4.87 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,233 Biotechnology companies, Capricor Therapeutics ranks worse than 76.07% on this metric.
The historical rank and industry rank for Capricor Therapeutics's PB Ratio or its related term are showing as below:
CAPR'
s PB Ratio Range Over the Past 10 Years
Min: 0.82 Med: 4.11 Max: 1486.96
Current: 6.11
During the past 13 years, Capricor Therapeutics's highest PB Ratio was 1486.96. The lowest was 0.82. And the median was 4.11.
CAPR's PB Ratio is ranked worse than 76.07% of 1233
companies
in the Biotechnology industry
Industry Median: 2.83
vs CAPR: 6.11
During the past 12 months, Capricor Therapeutics's average Book Value Per Share Growth Rate was 72.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 125.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 32.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Capricor Therapeutics was 125.10% per year. The lowest was -192.40% per year. And the median was -38.85% per year.
Back to Basics: PB Ratio
Capricor Therapeutics (NAS:CAPR) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Capricor Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Capricor Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Capricor Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Capricor Therapeutics (CAPR) has a PB Ratio of 6.11 as of Jun. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Capricor Therapeutics and its competitors. This is 49% above median its historical median of 4.11. Over the past decade, Capricor Therapeutics' PB Ratio has ranged from 0.82 to 1,486.96. According to the industry distribution chart, Capricor Therapeutics ranks #938 out of 1233 companies in the Biotechnology industry, placing it in the top 76.1%.
Is Capricor Therapeutics' PB Ratio too high?
Capricor Therapeutics' current PB Ratio of 6.11 is 49% above median its 10-year median of 4.11. Over the past 10 years, this metric has ranged from a low of 0.82 to a high of 1,486.96. The Biotechnology industry median PB Ratio is 2.83. Capricor Therapeutics' value of 6.11 is 115.9% above this industry median. Based on the distribution chart, Capricor Therapeutics ranks #938 out of 1233 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Capricor Therapeutics has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Capricor Therapeutics' PB Ratio compare to SNDX and SLS?
According to the Biotechnology industry distribution chart, Capricor Therapeutics ranks #938 out of 1233 companies for PB Ratio. This places Capricor Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.83. Capricor Therapeutics' value of 6.11 is 115.9% above this benchmark. Historically, Capricor Therapeutics' own PB Ratio has ranged from 0.82 to 1,486.96 over the past decade. While the company's 10-year median is 4.11 vs. the industry median of 2.83, Capricor Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Capricor Therapeutics's current PB Ratio of 6.11 is 115.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Capricor Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Capricor Therapeutics's current PB Ratio is 6.11, which is 49% above median its own 10-year median of 4.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Capricor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Capricor Therapeutics (CAPR) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.87, compared to a current price of $29.51 — trading 506% above its estimated fair value. The current PB Ratio is 6.11, which is 49% above median its 10-year median of 4.11 and 115.9% above the Biotechnology industry median of 2.83. Capricor Therapeutics' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Capricor Therapeutics (CAPR), the current PB Ratio is 6.11 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Capricor Therapeutics (CAPR) Overvalued in 2026?
Based on GuruFocus' analysis, Capricor Therapeutics stock appears to be overvalued.
The current stock price of $29.51 is trading 506% above its estimated GF Value™ of $4.87.
GuruFocus considers Capricor Therapeutics to be Significantly Overvalued.
Key valuation signals for CAPR:
PB Ratio: 6.11 (49% above median its 10-year median of 4.11)
GF Value™: $4.87 vs. price of $29.51 (506% above fair value)
Industry Position: 115.9% above the Biotechnology median (#938 of 1233)
No single metric tells the full story. See the CAPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
37GF Score
Get the complete analysis for CAPR
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAPR has been successfully added to your 
